With an aim to expand the existing production capacity of its synthetic pharmaceutical CDMO business by 30 %, AGC has plans to invest 100 million dollars to develop a new facility in Spain for its subsidiary AGC Pharma Chemicals Europe. The new facility will focus on highly potent active pharmaceutical ingredients due to its high market demand.
Read on